Alendronate (Fosamax)

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Juvenile Osteoporosis

Conditions

Juvenile Osteoporosis, Low Bone Density, Fractures

Trial Timeline

Jul 1, 2009 → Oct 1, 2010

NCT ID

NCT00920075

About Alendronate (Fosamax)

Alendronate (Fosamax) is a pre-clinical stage product being developed by Merck for Juvenile Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00920075. Target conditions include Juvenile Osteoporosis, Low Bone Density, Fractures.

What happened to similar drugs?

7 of 20 similar drugs in Juvenile Osteoporosis were approved

Approved (7) Terminated (1) Active (13)

✅Tocilizumab + NSAIDs + CSs + MTXRocheApproved

✅TocilizumabRocheApproved

✅VIMOVO 250/20 + VIMOVO 375/20 + VIMOVO 500/20AmgenApproved

✅800 mg ibuprofen/26.6 mg famotidineAmgenApproved

✅methotrexate + methotrexate - etanercept - prednisolone armAmgenApproved

✅SulfasalazinePfizerApproved

✅Celecoxib + NaproxenPfizerApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00920075	Pre-clinical	Completed	Jul 1, 2009	Oct 1, 2010	Juvenile Osteoporosis

Competing Products

20 competing products in Juvenile Osteoporosis

See all competitors

Product	Company	Stage	Hype Score
PLX-200 + Placebo	Polaryx Therapeutics	Phase 3	37
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
Adalimumab	Eisai	Phase 3	40
Abatacept	Ono Pharmaceutical	Phase 3	40
Ixekizumab + Adalimumab	Eli Lilly	Phase 3	44
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib	Eli Lilly	Phase 3	47
Baricitinib + Tocilizumab	Eli Lilly	Phase 3	47
adalimumab + Methotrexate	AbbVie	Pre-clinical	26
Upadacitinib	AbbVie	Phase 1	33
Upadacitinib + Tocilizumab	AbbVie	Phase 3	47
Adalimumab + Risankizumab	AbbVie	Phase 3	47
Adalimumab	AbbVie	Phase 3	40
naproxen + esomeprazole	AstraZeneca	Phase 1	29
canakinumab	Novartis	Phase 3	40
Secukinumab	Novartis	Phase 1	36
ACZ885 150 mg (Canakinumab)	Novartis	Phase 3	40